Denis Knight, DO
Family Medicine · Wichita, KSNPI 1235190919
Payments from drug & device makers
Across 248 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$698
- AbbVie$679
- AstraZeneca$637
- Lilly USA, LLC$304
- Paratek Pharmaceuticals, Inc.$250
- Bayer$240
- plus $1K from 28 others
What the payments were for
- Food & beverage$4,186100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $698 |
| AbbVie(2 entities) | 45 | $679 |
| AstraZeneca | 37 | $637 |
| Lilly USA, LLC | 20 | $304 |
| Paratek Pharmaceuticals, Inc. | 14 | $250 |
| Bayer | 16 | $240 |
| Abbott | 11 | $210 |
| Amgen | 10 | $170 |
| Johnson & Johnson | 7 | $106 |
| Eisai Inc. | 6 | $106 |
| GSK | 7 | $103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $79 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Sanofi Pasteur Inc. | 3 | $50 |
| Pfizer | 3 | $49 |
| Astellas Pharma US Inc | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Xeris Pharmaceuticals, Inc. | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Medtronic | 1 | $27 |
| Baxter Healthcare | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Merck | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Apria Healthcare LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$118
How this compares
$4,206 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 461 | $160,596 |
| OzempicSemaglutide | 101 | $105,708 |
| FarxigaDapagliflozin Propanediol | 63 | $79,070 |
| AustedoDeutetrabenazine | 26 | $66,759 |
| VraylarCariprazine Hcl | 55 | $48,564 |
| JanuviaSitagliptin Phosphate | 43 | $31,548 |
| Invega SustennaPaliperidone Palmitate | 11 | $27,144 |
| XareltoRivaroxaban | 39 | $26,176 |
| JardianceEmpagliflozin | 48 | $26,151 |
| TradjentaLinagliptin | 60 | $24,734 |
| MyrbetriqMirabegron | 53 | $18,230 |
| TrulicityDulaglutide | 17 | $17,121 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $16,240 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $16,080 |
| KerendiaFinerenone | 14 | $15,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $49 | $165,201480 claims |
| Novo NordiskOzempic | $698 | $105,708101 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $637 | $86,05474 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $106 | $53,32050 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17 | $50,885108 claims |
| AbbVieVraylar | $679 | $48,56455 claims |
| MerckJanuvia | $14 | $31,54843 claims |
| GSKIncruse Ellipta, Anoro Ellipta, Breo Ellipta | $103 | $19,35147 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $18,23053 claims |
| Lilly USA, LLCTrulicity | $304 | $17,12117 claims |
| BayerKerendia | $240 | $15,37914 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $59 | $5,90111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Wichita
- Terry PolingWichita$24.2M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Brandon AllemanWichita$3M
- Tracy KleinWichita$2.7M
- William SimonWichita$1.1M
- Tana GoeringWichita$1.1M
- Gregory LakinWichita$897K
- Timothy KoehlerWichita$675K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.